Effectiveness, toxicity, and economic evaluation of ipilimumab for the treatment of patients with metastatic melanoma in the Spanish outpatient setting

Anti-Cancer Drugs

Volumn 27, Issue 7, 2016, Pages 679-684

  Guglieri López, Beatriz ^a   Pérez Pitarch, Alejandro ^b   Oltra, Begoña Porta ^a   Ferriols Lisart, Francisco ^b   Royo Peiró, Ángeles ^a   Climente Martí, Mónica ^a  

^a HOSPITAL UNIVERSITARIO DR PESET   (Spain)

^b HOSPITAL CLÍNICO UNIVERSITARIO   (Spain)

Author keywords

Cost effectiveness; Ipilimumab; Metastasic melanoma; Survival outcomes

Indexed keywords

DABRAFENIB; DACARBAZINE; FOTEMUSTINE; IPILIMUMAB; TEMOZOLOMIDE; TRAMETINIB; ANTINEOPLASTIC AGENT; MONOCLONAL ANTIBODY;

ADULT; ANEMIA; ARTICLE; BONE MARROW TOXICITY; CANCER COMBINATION CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CANCER MORTALITY; CANCER PATIENT; CANCER STAGING; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL EFFECTIVENESS; CLINICAL EVALUATION; COHORT ANALYSIS; COST EFFECTIVENESS ANALYSIS; COST OF ILLNESS; DIARRHEA; DRUG COST; DRUG EFFICACY; DRUG SAFETY; FEMALE; FOLLOW UP; GASTROINTESTINAL HEMORRHAGE; HUMAN; LEUKOPENIA; MALE; METASTATIC MELANOMA; MULTICENTER STUDY (TOPIC); MULTIPLE CYCLE TREATMENT; NEUTROPENIA; OBSERVATIONAL STUDY; OUTPATIENT CARE; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RASH; RETROSPECTIVE STUDY; SPAIN; SYSTEMIC THERAPY; THROMBOCYTOPENIA; CLINICAL TRIAL; COST BENEFIT ANALYSIS; ECONOMICS; MELANOMA; METASTASIS; MIDDLE AGED; MULTICENTER STUDY; PATHOLOGY;

ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; COST-BENEFIT ANALYSIS; FEMALE; HUMANS; MALE; MELANOMA; MIDDLE AGED; NEOPLASM METASTASIS; RETROSPECTIVE STUDIES;

EID: 84964005698     PISSN: 09594973     EISSN: 14735741     Source Type: Journal    
DOI: 10.1097/CAD.0000000000000368     Document Type: Article

References (16)

1. American Cancer Society. Cancer facts and figures 2011. Atlanta, GA: American Cancer Society; 2011.
2. Hodi FS, O'Day SJ, McDermott DF, Weber RW, Sosman JA, Haanen JB, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 2010; 363:711-723.
3. Surveillance, epidemiology and end results (SEER) Stat Fact Sheets: melanoma of the skin. National Cancer Institute, Bethesda, MD; 2012. Available at: http://seer.cancer.gov/statfacts/html/melan.html. [Accessed 13 July 2012].
4. Hollestein LM, van den Akker SA, Nijsten T, et al. Trends of cutaneous melanoma in The Netherlands: increasing incidence rates among all Breslow thickness categories and rising mortality rates since 1989. Ann Oncol 2012; 23:524-530.
5. Green AC, Williams GM, Logan V, Strutton GM. Reduced melanoma after regular sunscreen use: randomized trial follow-up. J Clin Oncol 2011; 29:257-263.
6. Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer 2010; 127:2893-2917.
7. Chapman PB, Einhorn LH, Meyers ML, Saxman S, Destro AN, Panageas KS, et al. Phase III multicenter randomized trial of the Dartmouth regimen versus dacarbazine in patients with metastatic melanoma. J Clin Oncol 1999; 17:2745-2751.
8. Middleton MR, Grob JJ, Aaronson N, Fierlbeck G, Tilgen W, Seiter S, et al. Randomized phase III study of temozolomide versus dacarbazine in the treatment of patients with advanced metastatic malignant melanoma. J Clin Oncol 2000; 18:158-166.
9. Avril MF, Aamdal S, Grob JJ, Hauschild A, Mohr P, Bonerandi JJ, et al. Fotemustine compared with dacarbazine in patients with disseminated malignant melanoma: a phase III study. J Clin Oncol 2004; 22:1118-1125.
10. Dummer R, Hauschild A, Lindenblatt N, Pentheroudakis G, Keilholz U. Cutaneous melanoma: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol 2015; 26 (Suppl 5):v126-v132.
11. Hodi FS, O'Day SJ, McDermott DF, Weber RW, Sosman JA, Haanen JB, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 2010; 363:711-723.
12. LEGISLATIVE DECREE 1/2005, dated February 25, from the Consell de la Generalitat, by which approves the Consolidated Law on Taxes of the Generalitat. pp 9589-9615. Available at: http://www.docv.gva.es/rlgv/fileadmin/datos/pdfs-notas/2005/L-Tasas-D-Leg-1-2005-por-Ley-2-2012.pdf. [Accessed 12 January 2016].
13. Law 9/2011 of 26 December, of Fiscal Measures, Administrative and Financial Management, and Organization of the Generalitat. Available at: http://www.san.gva.es/documents/151744/2847194/LEY-DE-TASAS-2015.docx. [Accessed 12 January 2016].
14. Bang H, Zhao H. Median-based incremental cost-effectiveness ratio (ICER). J Stat Theory Pract 2012; 6:428-442.
15. Barzey V, Atkins MB, Garrison LP, Asukai Y, Kotapati S, Penrod JR. Ipilimumab in 2nd line treatment of patients with advanced melanoma: a costeffectiveness analysis. J Med Econ 2013; 16:202-212.
16. Curl P, Vujic I, van 't Veer LJ, Ortiz-Urda S, Kahn JG. Cost-effectiveness of treatment strategies for BRAF-mutated metastatic melanoma. PLoS One 2014; 9:e107255.